10 November 2015
DETAILS
The Board of Directors of Arkema met
on 9 November 2015
to review the Group’s consolidated
accounts for 3 rd quarter 2015
• Strong EBITDA increase to €286 million,
+38% up on 3Q 2014 (€207 million)
* Excluding Bostik contribution, significant improvement
driven by Industrial Specialties
* Good performance of Bostik strengthened
by first benefits from synergies
• EBITDA margin increase to 14.7% (14.0% in 3Q 2014)
despite Bostik dilutive effect
• Adjusted net income1 of €95 million up +36%
on 3Q 2014, i.e. €1.27 per share
• Very strong cash flow generation and
decrease in net debt compared to
end June 2015 at €1,632 million, i.e. 42% gearing
• €1,946 million sales, +32% up on 3Q 2014
including Bostik contribution of +28%
VIEW ARKEMA Q3 2015 FULL PRESETATION
WWW.CHEMWINFO.COM BY KHUN PHICHAI
